Sarepta Accused Of Misleading Investors On MD Drug

Law360, New York (January 28, 2014, 4:56 PM EST) -- A Sarepta Pharmaceuticals Inc. shareholder filed a class action against the company in Massachusetts federal court Monday, alleging it intentionally misled investors about muscular dystrophy drug eteplirsen's chances of hitting the open market.

Mark A. Corban claims that he and potentially thousands of others who bought or sold securities in Sarepta between July 24 and Nov. 12, 2013, based their decisions on incomplete or deceiving information the company had provided about eteplirsen, Sarepta's leading candidate for production.

“Had plaintiff and the other members of the class...
To view the full article, register now.